- Home
- ACIC vs PCRX Comparison
ACIC vs PCRX Comparison
Compare ACIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | PCRX |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.1M | 1.0B |
| IPO Year | 2007 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PCRX |
|---|---|---|
| Price | $11.08 | $22.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $37.20 |
| AVG Volume (30 Days) | 157.2K | ★ 629.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | 39.61 | ★ 107.44 |
| EPS | ★ 2.15 | 0.16 |
| Revenue | $335,439,000.00 | ★ $541,533,000.00 |
| Revenue This Year | N/A | $7.10 |
| Revenue Next Year | $1.00 | $9.15 |
| P/E Ratio | ★ $5.23 | $141.25 |
| Revenue Growth | 13.07 | ★ 26.04 |
| 52 Week Low | $9.97 | $18.80 |
| 52 Week High | $13.06 | $27.99 |
Technical Indicators
Market Signals| Indicator | ACIC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 51.67 |
| Support Level | $10.93 | $22.57 |
| Resistance Level | $11.28 | $23.91 |
| Average True Range (ATR) | 0.22 | 0.89 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 10.34 | 59.18 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.